CStone partners with Istituto Gentili for sugemalimab in Europe

CStone Pharmaceuticals announced an exclusive licensing agreement with Istituto Gentili to commercialize sugemalimab, an anti-PD-L1 monoclonal antibody, in Western Europe and the United Kingdom. Under the terms of the agreement, Gentili will receive exclusive commercialization rights in 23 European countries. CStone is eligible to receive up to USD192.5 million in upfront, regulatory, and commercial milestone payments. Furthermore, CStone will supply sugemalimab and recognize close to 50% of net sales in the licensed territories as revenue. The partnership aims to accelerate patient access to sugemalimab in Europe, where it is approved for first-line treatment of stage IV non-small cell lung cancer. This agreement expands sugemalimab's global reach to over 60 countries and regions and is the fourth major regional partnership secured by CStone. Istituto Gentili will lead all local regulatory and commercial operations in the covered regions.